Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis

2017 ◽  
Vol 47 (4) ◽  
pp. 516-525 ◽  
Author(s):  
F. Mettke ◽  
B. Schlevogt ◽  
K. Deterding ◽  
A. Wranke ◽  
A. Smith ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
De Novo ◽  
Direct Acting Antivirals ◽  
Short Term ◽  
Direct Acting ◽  
De Novo Hepatocellular Carcinoma

scholarly journals Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2602 ◽  
Author(s):  
Eiichi Ogawa ◽  
Hideyuki Nomura ◽  
Makoto Nakamuta ◽  
Norihiro Furusyo ◽  
Eiji Kajiwara ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
De Novo ◽  
Incidence Rates ◽  
Annual Incidence ◽  
Multicenter Cohort Study ◽  
History Of ◽  
Direct Acting

Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antivirals (DAAs). However, it remains unclear if DAAs themselves have an influence on or facilitate the development of HCC. This multicenter cohort study included CHC patients without a history of HCC who achieved HCV elimination by DAAs. Cohorts of 835 patients treated with a sofosbuvir (SOF)-based regimen and 835 treated with a SOF-free regimen were matched 1:1 by propensity scoring with nine variables to evaluate differences in HCC incidence. The median observation period was 3.5 years. Sixty-nine cases of HCC were found during 5483.9 person-years (PY) over the entire follow-up period. The annual incidence was similar for both groups (SOF-based 1.25 and SOF-free 1.27 per 100 PY, respectively: adjusted hazard ratio (HR) 1.26, 95% confidence interval (CI) 0.75–2.12, p = 0.39). However, the annual incidence within the first two years was higher for patients treated with SOF than for those without, but did not reach significance (1.50 and 0.97 per 100 PY incidence rates, respectively: adjusted HR 2.05, 95% CI 0.98–4.25, p = 0.06). In summary, DAA treatment with SOF was not associated with an increase in the development of de novo HCC.

lnc‐HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct‐acting antivirals therapy

2020 ◽  
Vol 59 (12) ◽  
pp. 1382-1391
Author(s):  
Nashwa El‐Khazragy ◽  
Amal Ali Elshimy ◽  
Safaa Shawky Hassan ◽  
Mohamed Hafez Shaaban ◽  
Ahmed Hamed Bayoumi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Direct Acting Antivirals ◽  
Genotype 4 ◽  
Direct Acting

A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrotic patients treated with direct-acting antivirals

2020 ◽  
Vol 73 ◽  
pp. S208-S209
Author(s):  
Elisabetta Degasperi ◽  
Enrico Galmozzi ◽  
Serena Pelusi ◽  
Roberta D’ambrosio ◽  
Roberta Soffredini ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Risk Score ◽  
Genetic Risk ◽  
De Novo ◽  
Genetic Risk Score ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
De Novo Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document